Physician profile
Amy E Harp
NPI 1760750566
$608.39
in general payments reported to CMS, 2019-2025
14 companies · $15.37 in 2025
The $15.37 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $174 · 2023: $144 · 2024: $162 · 2025: $15.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $166.77 | 2023-2024 | Rexulti |
| Eisai INC. | $122.55 | 2024 | |
| Abbott Laboratories | $45.10 | 2021-2022 | |
| Lilly USA, LLC | $44.93 | 2022 | |
| Neurocrine Biosciences, INC. | $39.76 | 2021 | |
| Amgen INC. | $36.25 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.78 | 2022 | |
| Avanir Pharmaceuticals, INC. | $28.90 | 2021-2022 | |
| Scpharmaceuticals INC. | $16.33 | 2024 | |
| Medline Industries LP | $15.37 | 2025 | |
| Novo Nordisk INC | $15.37 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.69 | 2022 | |
| Biogen, INC. | $14.33 | 2021 | |
| Glaxosmithkline, LLC. | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Harp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.